The corneal epitheliotrophic abilities of lyophilized powder form human platelet lysates
Journal
PLoS ONE
Journal Volume
13
Journal Issue
3
Date Issued
2018
Author(s)
Abstract
Purpose To evaluate whether lyophilized human platelet lysate (HPL) powder can preserve the growth factor concentrations and epitheliotrophic properties of liquid HPL, and potentially be used as a clinically-friendly treatment option. Methods Two commercialized liquid HPLs, UltraGRO TM (Helios, Atlanta, GA) and PLTMax (Mill Creek, Rochester, MI), were obtained and converted to lyophilized powder. After redissolution, lyophilized powder HPLs were compared with liquid HPLs, as well as human peripheral serum (HPS) and fetal bovine serum (FBS) in liquid or redissolved lyophilized powder forms. Concentrations of epidermal growth factor (EGF), transforming growth factor-?1 (TGF-?1), platelet-derived growth factor-AB (PDGF-AB) and platelet-derived growth factor- BB (PDGF-BB) were evaluated by enzyme-linked immunosorbent assay (ELISA). Human corneal epithelial cell line was incubated with the blood derivatives and evaluated for cell migration with scratch-induced directional wounding and proliferation with MTS assays. Cell differentiation was examined by transepithelial electrical resistance (TEER). Fluorescein staining and in vivo confocal microscopy were used to evaluate in vivo corneal epithelial wound healing in Sprague-Dawley rats that underwent corneal debridement and topical application of liquid and redissolved powder HPLs. Results Liquid form and redissolved lyophilized powder form HPLs had similar concentrations of EGF, TGF-?1, PDGF-AB and PDGF-BB. In vitro experiments on cell migration, proliferation and differentiation and rat models on wound healing demonstrated no significant difference between the liquid and redissolved lyophilized powder forms for HPLs, HPS and FBS. In vivo confocal microscopy revealed similar wound healing process at different layers of cornea after corneal epithelial debridement between liquid form and redissolved lyophilized power form of HPLs. Conclusions The redissolved lyophilized powder form of both commercialized HPLs showed similar growth factor concentrations and corneal epitheliotrophic abilities compared to the liquid form. Results suggest that the properties of liquid HPLs can be retained despite lyophilization and that lyophilized HPLs can be a treatment option for corneal epithelial disorders. ? 2018 Chen et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
SDGs
Other Subjects
agents acting on the eye; epidermal growth factor; fluorescein; human platelet lysate; platelet derived growth factor AB; platelet derived growth factor BB; pltmax; transforming growth factor beta1; ultragro tm; unclassified drug; animal cell; animal experiment; animal model; animal tissue; Article; cell differentiation; cell migration; cell proliferation; concentration (parameters); confocal microscopy; controlled study; cornea disease; cornea epithelium; debridement; electric resistance; enzyme linked immunosorbent assay; human; human cell; in vitro study; in vivo study; lyophilisate; male; MTS assay; multiple cycle treatment; nonhuman; powder; rat; staining; transepithelial electrical resistance; treatment duration; wound healing; animal; cell line; cell motion; cornea epithelium; cytology; electrophysiology; metabolism; pathology; physiology; thrombocyte; tissue preservation; wound healing; Animals; Blood Platelets; Cell Differentiation; Cell Line; Cell Movement; Cell Proliferation; Electrophysiological Phenomena; Epithelium, Corneal; Humans; Male; Rats; Tissue Preservation; Wound Healing
Type
journal article